**ORIGINAL ARTICLE** 



# Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer's disease

Friederike Völter<sup>1,2</sup> Sebastian Eckenweber<sup>1</sup> · Maximilian Scheifele<sup>1</sup> · Florian Eckenweber<sup>1</sup> · Fabian Hirsch<sup>3</sup> · Nicolai Franzmeier<sup>3,4,5</sup> · Annika Kreuzer<sup>1</sup> · Maria Griessl<sup>1</sup> · Anna Steward<sup>3</sup> · Daniel Janowitz<sup>3</sup> · Carla Palleis<sup>4,6,7</sup> · Alexander Bernhardt<sup>6,7</sup> · Jonathan Vöglein<sup>4,6,7</sup> · Anna Stockbauer<sup>6</sup> · Boris-Stephan Rauchmann<sup>8</sup> · Florian Schöberl<sup>6</sup> · Elisabeth Wlasich<sup>6</sup> · Katharina Buerger<sup>3,7</sup> · Olivia Wagemann<sup>6</sup> · Robert Perneczky<sup>6</sup> · Endy Weidinger<sup>6,7</sup> · Günter Höglinger<sup>4,6,7</sup> · Johannes Levin<sup>4,6,7</sup> · Matthias Brendel<sup>1,4,7</sup> · Sonja Schönecker<sup>6</sup>

Received: 23 November 2024 / Accepted: 19 February 2025 / Published online: 28 February 2025 © The Author(s) 2025

#### Abstract

**Purpose** Clinical staging in individuals with Alzheimer's disease (AD) typically relies on neuropsychological testing. Recognizing the imperative for an objective measure of clinical AD staging, regional perfusion in early-phase β-amyloid-PET may aid as a cost-efficient index for the assessment of neurodegeneration severity in patients with Alzheimer's disease. **Methods** Regional perfusion deficits in early-phase β-amyloid-PET as well as neuropsychological testing (max. 90 days delay) were evaluated in 82 patients with biologically defined AD according to the ATN classification. In reference to the Braak staging system patients were classified into the groups stage<sup>0</sup>, stage<sup>1-II+</sup>, stage<sup>1-VI+</sup>, and stage<sup>atypical+</sup> according to regional perfusion deficits in regions of interest (ROIs) published by the Alzheimer's Disease Neuroimaging Initiative. Multiple regression analysis controlling for age, gender, and education was used to evaluate the association of regional z-scores on perfusion-phase PET with clinical scores for all patients and with annual decline of cognitive performance in 23 patients with follow-up data.

**Results** Patients classified as stage<sup>0</sup> and stage<sup>I–II+</sup> demonstrated significantly superior neuropsychological performance compared to those classified as stage<sup>I–IV+</sup> and stage<sup>I–VI+</sup>. Lower cognitive performance was associated with decreased perfusion in early-phase  $\beta$ -amyloid-PET globally and regionally, with the most pronounced association identified in the left temporal lobe. Mean z-scores on early-phase PET in temporal and parietal regions offered a robust prediction of future annual decline in MMSE and sum scores of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer's Disease) test battery. **Conclusion** Regional and global perfusion deficits in early-phase  $\beta$ -amyloid-PET can serve as an objective index of neuro-degeneration severity and may act as prognostic markers of future cognitive decline in AD.

Keywords Early-phase  $\cdot$   $\beta$ -amyloid  $\cdot$  PET/CT  $\cdot$  Alzheimer's disease  $\cdot$  Neurodegenerative diseases  $\cdot$  Neuropsychological testing  $\cdot$  MMSE  $\cdot$  CERAD

Friederike Völter Friederike.voelter@med.uni-muenchen.de

- <sup>1</sup> Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany
- <sup>2</sup> Department of Internal Medicine IV, University Hospital of Munich, LMU Munich, Munich, Germany
- <sup>3</sup> Institute for Stroke and Dementia Research (ISD), Munich, Germany
- <sup>4</sup> Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

- <sup>5</sup> Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal and Gothenburg, Sweden
- <sup>6</sup> Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany
- <sup>7</sup> German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- <sup>8</sup> Department of Neuroradiology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

# Introduction

For the in vivo diagnosis of Alzheimer's disease (AD), the "A/T/N" classification system, focusing on β-amyloid deposition (A), pathologic tau (T), and neuronal injury (N), is widely accepted for the biological definition of the disease [1]. These ATN criteria can be evaluated using cerebrospinal fluid (CSF), plasma, and imaging biomarkers. Among imaging biomarkers, FDG-PET is commonly used to assess neuronal injury [1-3]. Regional neuronal injury measured by FDG-PET has been associated with neurocognitive performance on clinical tests; however, its reliability as a cognitive marker is limited by variations in cognitive resilience and unmeasured copathologies [2, 4, 5]. Beyond FDG-PET, early-phase β-amyloid-PET imaging provides an alternative means of assessing neuronal injury, utilizing tracer extraction from blood as a perfusion surrogate [6-10]. The strong correlation between regional uptake in the perfusion phase of beta-amyloid PET and regional neuronal damage in FDG-PET is likely driven by neurovascular coupling of cerebral blood flow and metabolic demand [11–13].

A dual-phase acquisition protocol in  $\beta$ -amyloid-PET imaging enables not only the reliable detection of cerebral  $\beta$ -amyloid plaques (i.e., A) [14–19] but also the assessment of neuronal injury (i.e., N). The combination of perfusionsurrogate imaging and  $\beta$ -amyloid plaque detection within a single scan reduces the need for multiple imaging modalities and improving efficiency for patients, physicians, and the healthcare system.

While imaging biomarkers provide objective measures of AD pathology, their clinical relevance must be validated against neurocognitive performance. The clinical severity of AD is commonly screened using the Mini-Mental state examination (MMSE) [20, 21]. To further assess cognitive decline in more detail and thus confirm suspicion of cognitive decline by MMSE, more advanced neuropsychological test batteries such as the CERAD-Plus test battery are available [22]. For therapeutic studies, a crucial necessity arises for objective biomarkers that precisely correlate with disease severity, progression rate, and underlying pathology. There is limited research on the association between regional perfusion deficit in perfusion-phase β-amyloid-PET and clinical severity of dementia [23]. By comparing regional perfusion deficits, current neuropsychological test results, and future annual cognitive decline, we aimed to investigate the agreement between early-phase β-amyloid-PET and cognitive performance of patients with AD. Additionally, we explored whether perfusion-phase  $\beta$ -amyloid PET can serve as a biomarker for in vivo staging of disease severity, potentially enhancing diagnostic accuracy and disease monitoring.

# Methods

#### **Patient acquisition**

All patients receiving dual-phase  $\beta$ -amyloid-PET between September 2013 and October 2021 were evaluated for inclusion in the study. Inclusion criteria were amyloid-positivity on visual inspection of the PET scan [1] as well as an interval of less than 90 days between PET scan and neuropsychological testing (e.g. MMSE and CERAD-PLUS test battery). Patients with atypical AD or mixed pathology were excluded.

#### **Clinical evaluation**

Clinical severity of dementia was assessed using the MMSE and CERAD-PLUS test battery by neuropsychologists and physicians of the Institute for Stroke and Dementia Research, the Department of Psychiatry and Psychotherapy, and the Department of Neurology at LMU University Hospital, LMU Munich, Munich, Germany [20, 22]. In cases, when MMSE was not available, Montreal Cognitive Assessment Scores were used.

#### **Radiosynthesis and image acquisition**

The radiosynthesis of [<sup>18</sup>F]flutemetamol and [<sup>18</sup>F]florbetaben was performed as described previously. After semipreparative high-performance liquid chromatography, radiochemical purity was >97% [24]. PET images were acquired with a Biograph 64 or a Siemens mCT PET/CT scanner (Siemens Healthineers, Erlangen, Germany) at the Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Germany. The mean injected dose of [<sup>18</sup>F]florbetaben (*n*=36) was 286 MBq (±52) / 7.73 mCi (±1.41). The mean injected dose of [<sup>18</sup>F]flutemetamol (*n*=47) was 177 MBq (±22) / 4.78 mCi (±0.59). The perfusion-weighted scan was acquired 0–10 min post-injection as a single frame [6].

#### Image processing

Brains were parcellated into 47 regions using the automated anatomical labeling (AAL) atlas with Hermia Neurology Package Version 6.1.4 (Brass) (Hermes Medical Solutions, Stockholm) [25]. Regional tracer activity of single brain regions was normalized to the global mean activity of the patient and related to a built-in normal cohort of FDG-PET (z-score) as decribed previously [7]. Voxel-based volumeweighted mean z-scores were calculated for all cortical brain lobes of both sides. Furthermore, we investigated z-scores in predefined volumes of interest in reference to the Braak stage composite regions of interest published by the Alzheimer's Disease Neuroimaging Initiative [26]. Specifically, regions I/II were defined as the mesiotemporal lobes. Regions III/IV included the mesio-occipital lobes, the mid and inferior temporal cortex, the temporal pole, the anterior and posterior cingulate and the insular cortex. Regions V/VI encompassed the orbitofrontal cortex, the frontal lateral cortex, the frontal medial cortex, the superior temporal cortex, the occipital cortex, the superior and inferior parietal cortex, the precuneus and the post- and precentral cortex.

#### **Regional staging with early-phase PET data**

A ratio was calculated by dividing the voxel-weighted mean z-score of regions I/II, III/IV and V/VI of the patient's PET by the voxel-weighted mean z-score of the respective regions in patients with an MMSE-score above 27. Based on previous studies evaluating PET-based classification of disease severity, a cut-off of -1.3 was used to determine whether the perfusion in a volume of interest (VOI) was abnormal [27]. Patients were classified as stage<sup>I-II+</sup> when only the regions I/I surpassed the cut-off of 1.3. When the regions I/II as well as the regions III/IV surpassed the cut-off, but not regions V/VI, patients were classified as stage<sup>I-IV+</sup>. When the regions I/II, III/IV, and V/VI all surpassed the cut-off, patients were staged stage<sup>I-VI+</sup>. Patients with no region surpassing the



Fig. 1 Flow chart of patient selection

threshold were labelled stage<sup>0</sup>. Patients deviating from this staging scheme were labelled stage<sup>atypical+</sup> [27].

#### Statistics

Patients were divided into 5 groups according to their MMSE score (group I: MMSE-score 28–30, group II: MMSE-score 24–27, group III: MMSE-score 18–23, group IV: MMSE-score 10–17, group V: MMSE-score <9). For three patients, MMSE scores were not available. Montreal Cognitive Assessment scores were converted to an equivalent MMSE score by Lawton et al. [28, 29]. Normal distribution was tested using the Shapiro-Wilk test. Quantitative values were reported with mean±standard deviation when normally distributed and with median and interquartile range when not normally distributed. For multi-comparison testing volume-weighted mean z-scores of all groups were compared by Kruskal-Wallis-test or ANOVA followed by Tukey's multiple comparisons test.

Clinical follow-up data were available in 23 patients. To calculate percentage annual decline the decrease of MMSE scores and CERAD sum scores was divided by the study interval in years.

Volume-weighted mean z-scores of all brain lobes and single brain regions as well as volume-weighted mean z-scores of regions I and II, regions III and IV, as well as regions V and VI were compared with clinical test scores and annual percentage decline by applying multiple linear regression correcting for age, gender and years of education.

# Results

#### Study cohort

379 patients were screened for inclusion in the study. After applying the inclusion and exclusion criteria described, a total of 82 patients were included in the study. Specific reasons for inclusion and exclusion of patients are shown in a flowchart in Fig. 1. Table 1 presents the neuropsychological test scores obtained from MMSE testing and the CERAD Plus test battery, categorizing patients into groups according to their MMSE test scores. No significant differences were observed in age, sex, and years of education among patient groups with varying clinical severity. Patients with decreased MMSE scores also showed significantly lower test scores in the CERAD Plus test battery evaluating the total score and most of the CERAD Plus subtests. Posthoc multiple comparisons tests are added in supplementary Table 1.

	All patients	MMSE 28-30	MMSE 24-27	MMSE 18-23	MMSE 10-17	$p^1$
Number of patients	82	14	36	21	11	
Mean age	71.3 (±8.8)	70.3 (±8.4)	71.8 (±6.9)	71.4 (±8.2)	73.1 (±8.6)	0.745
Sex (female/male)	(40/42)	(5/9)	(18/18)	(10/11)	(7/4)	0.557
Years of education	13.4 (±3.3)	14.6 (±3.7)	13.2 (±2.9)	12.6 (±2.8)	13.1 (±4.6)	0.366
MMSE score	23.4 (±4.8)	28.8 (±0.9)	25.2 (±1.0)	21.7 (±1.3)	13.6 (±2.6)	< 0.0001
CERAD test battery						
Total score	59.3 (±12.3)	68.9 (±8.6)	61.7 (±12.0)	52.3 (±9.3)	43.7 (±10.3)	< 0.0001
Word list learning	11.2 (±5.5)	14.5 (±5.2)	11.8 (±5.6)	11.1 (±3.3)	4.7 (±4.6)	< 0.0001
Word list recall	2.9 (±2.1)	5.2 (±1.8)	3.1 (±1.8)	1.8 (±1.5)	0.5 (±0.9)	< 0.0001
Word list intrusions	2.7 (±3.7)	1.4 (±1.4)	2.7 (±3.5)	3.8 (±4.9)	1.7 (±2.2)	0.207
Word list recognition	8.5 (±1.9)	9.5 (±0.7)	8.4 (±1.9)	8.1 (±2.2)	7.9 (±2.2)	0.121
Word list discriminability	6.6 (±3.8)	7.4 (±4.0)	6.2 (±4.0)	7.3 (±3.5)	5.3 (±1.5)	0.382
Figure drawing	9.2 (±2.5)	10.9 (±0.3)	9.7 (±1.9)	7.7 (±2.8)	7.4 (±3.1)	< 0.0001
Figure recall	4.3 (±3.0)	7.2 (±3.0)	4.7 (±2.4)	2.9 (±2.1)	0.7 (±1.2)	< 0.0001
Semantic verbal fluency	13.8 (±5.0)	14.5 (±4.8)	15.5 (±4.3)	12.3 (±3.9)	9.0 (±6.1)	< 0.001
Phonematic verbal fluency	9.8 (±4.3)	11.3 (±4.0)	10.3 (±4.4)	8.7 (±3.4)	6.7 (±3.9)	0.027
Boston naming test	12.8 (±2.5)	13.6 (±1.5)	13.4 (±1.9)	12.3 (±1.9)	10.2 (±3.9)	< 0.001
Trail making test A	76.0 (±39.7)	57.6 (±22.5)	74.5 (±36.9)	84.2 (±31.5)	121.8 (±73.6)	0.004

Table 1 Patient cohort with categorization into groups based on MMSE scores

<sup>1</sup>Analysis of variance between displayed patient groups. The significance level was adjusted with Bonferroni correction to  $\alpha$ =0.003215. Significant p-values are displayed bold

# Data driven multilinear regression of regional perfusion deficits and cognitive performance in patients with AD

Multiple linear regression corrected for age, sex, and education showed a moderate association between MMSE scores and mean z-scores of both temporal lobes ( $r^2=0.37$ , p < 0.0001) and the global perfusion deficit ( $r^2 = 0.35$ , p < 0.001), as well as a weak association with perfusion deficits in the parietal lobes ( $r^2 = 0.09 - 0.14$ , p = 0.012 - 0.028), the precuneus ( $r^2=0.15-0.22$ , p<0.01), and the posterior cingulate cortex ( $r^2=0.20$ , p=0.001). CERAD-Plus total score, semantic word fluency, and the Boston naming test showed a moderate association with left frontal lobe, left temporal lobe, and global perfusion deficits ( $r^2 = 0.21 - 0.39$ , p < 0.0001 - 0.020). Trail making test (TMT) A demonstrated a significant moderate association with perfusion deficits in the temporal lobe, parietal lobe, posterior cingulate cortex (PCC), left precuneus, and occipital lobe as well as with the global perfusion deficit ( $r^2=0.19-0.41$ , p<0.0001-0.019). Almost all subtests were more strongly associated with left hemispheric compared to right hemispheric perfusion deficits. Detailed results are displayed in Table 2; Fig. 2.

# Association between perfusion deficits in predefined regions of interest and cognitive impairment

Multiple linear regression showed a significant association of perfusion deficits in all predefined regions I-VI with MMSE scores ( $r^2=0.24-0.33$ ; p<0.0001-0.003) and the CERAD-Plus sum score ( $r^2=0.20-0.27$ ; p=0.006-0.048). Within the CERAD-Plus subtests, the strongest association could be detected between perfusion deficits of regions III/IV and V/VI and the TMT A as well as semantic word fluency ( $r^2=0.27-0.36$ ; p<0.0001-0.0004). Additionally, there was a significant association between the items word list learning, word list recalling and perfusion deficit in regions I/II and III/IV ( $r^2=0.22-0.27$ ; p=0.007-0.031) and between the Boston Naming Test and all predefined regions ( $r^2=0.19-0.26$ ; p=0.006-0.027).

Patients that were classified as stage<sup>0+</sup> (n=25) and stage<sup>I-II+</sup> (n=11) had significantly better cognitive performance than patients that were classified as stage<sup>I-IV+</sup> (n=13) and stage<sup>I-VI+</sup> (n=17) when testing with MMSE (p=0.014) or CERAD-Plus test battery (p=0.044) at the time of imaging (Fig. 3A). 16/82 patients (19.5%) were classified as stage<sup>atypical+</sup>.

# Perfusion deficits across clinical stages and PETbased stages in patients with AD

All MMSE-related subgroups of patients with AD showed most severe perfusion deficits in the precuneus, the inferior parietal lobe, the mid temporal lobe, and the posterior cingulate gyrus (supplementary Table 2). With increasing severity of dementia, perfusion deficits measured by z-scores worsened in the described regions, as well as in various other regions like the occipital lobe, the anterior cingulate gyrus, and the insula (supplementary Table 1). In addition, z-scores decreased with increasing clinical severity in all PET-based stage-associated regions. While in the predefined region

	frontal		temporal		mesio- temporal	PCC par		etal	occipital		global
	right	left	right	left	both sides	both sides	right	left	right	left	
MMSE score	0.13	0.19	0.23	0.37	0.27	0.20	0.09	0.14	0.16	0.18	0.35
CERAD test battery											
Word list learning	0.14	0.19	0.19	0.27	0.28	0.12	0.07	0.14	0.13	0.12	0.26
Word list recall	0.09	0.16	0.12	0.21	0.26	0.10	0.06	0.07	0.14	0.15	0.21
Word list intrusions	0.09	0.15	0.10	0.16	0.19	0.12	0.07	0.08	0.18	0.18	0.22
Word list recognition	0.07	0.17	0.07	0.18	0.17	0.09	0.06	0.09	0.16	0.15	0.19
Word list discriminability	0.10	0.15	0.08	0.18	0.17	0.10	0.07	0.09	0.15	0.16	0.20
Figure drawing	0.07	0.19	0.10	0.17	0.19	0.11	0.17	0.09	0.18	0.19	0.22
Figure recall	0.09	0.15	0.13	0.15	0.20	0.11	0.08	0.09	0.19	0.17	0.22
Semantic verbal fluency	0.22	0.29	0.20	0.39	0.21	0.14	0.08	0.12	0.15	0.17	0.34
Phonematic verbal fluency	0.08	0.15	0.09	0.18	0.19	0.11	0.11	0.15	0.16	0.17	0.21
Boston naming test	0.14	0.24	0.16	0.31	0.26	0.11	0.06	0.09	0.13	0.12	0.26
Trail making test A	0.20	0.16	0.27	0.27	0.20	0.20	0.23	0.19	0.20	0.22	0.41
Total Score	0.17	0.23	0.13	0.28	0.22	0.12	0.07	0.09	0.15	0.16	0.26
The table displays the association r <sup>2</sup> . Significant associations were marked blue (light blue: p											

<b>Table 7</b> Multilinear regression of neuropsychological test results and regional pertusion deficits correcting for age, sex	ge sex and education
--	----------------------

The table displays the association  $r^2$ . Significant associations were marked blue (light blue: p < 0.05; medium blue: p < 0.01; dark blue: p < 0.001). The global perfusion deficit was calculated by the sum of all z-scores.

III/IV the decrease was statistically significant (p=0.02), statistical significance was not reached in regions I/II and V/VI (p=0.092 and 0.125). Perfusion deficits of the predefined stage-associated regions and an analysis of variance between patient groups stratified according to their MMSE score are displayed in Table 3 and in Fig. 3B). Post-hoc multiple comparisons test showed a significant difference of regional hypoperfusion in regions III/IV in patients with MMSE 10–17 compared to patients with MMSE 24–27 and MMSE 28–30 (p=0.041, respectively) (supplementary Table 3).

Figure 4 displays surface projections (3DSSP) of three exemplary patients with varying PET-based stages.

## 🖄 Springer

# Early-phase $\beta$ -amyloid-PET predicts future annual decline of MMSE test scores and CERAD-Plus test scores

For 23 patients, follow-up data of neuropsychological testing was available with a median follow-up time of 524 days (interquartile range: 358-1,011 days). Multiple linear regression analysis corrected for age, sex, and education revealed that perfusion deficits in the temporal lobes predicted future annual decline of MMSE scores ( $r^2=0.29$ ; p=0.037), while there was only a trend for global perfusion deficits ( $r^2=0.26$ , p=0.063, Fig. 5A). The strongest association was detected for the left inferior temporal cortex ( $r^2=0.38$ ; p=0.008). The perfusion deficit of the inferior parietal lobe showed a good prediction of future



**Fig. 2** Multilinear regression of neuropsychological test results and regional perfusion deficits corrected for age, sex and years of education. (A) and (B) partial correlation ( $r^2$ ) of regional perfusion deficits

annual decline of CERAD-Plus sum scores ( $r^2=0.39-0.41$ ; p=0.043-0.048). Results are displayed in Fig. 5. Voxelweighted mean z-scores of regions III/IV showed a significant association, voxel-weighted mean z-scores of regions V/VI a trend towards an association with annual percentage decline of MMSE scores ( $r^2=0.15$ ; p=0.033 and  $r^2=0.12$ ; p=0.054). There was no significant difference in percentage annual decline of patients grouped as stage<sup>0</sup>, stage<sup>I-II+</sup>, stage<sup>I-IV+</sup> and stage<sup>I-VI+</sup>. While 21 patients showed decreasing MMSE scores, there were 2 patients with an annual elevation in MMSE test scores (+7.0% and +13.9%). There were three patients with a small annual increase of CERAD Plus sum score (+1.1%, +1.5% and +7.1%).

# Discussion

In our study, we were able to demonstrate an association of global and regional perfusion deficits respectively in early-phase  $\beta$ -amyloid-PET with current cognitive performance in MMSE testing and CERAD-plus testing and future cognitive decline, as well as the feasibility of perfusion based staging thereby indicating the utility of earlyphase  $\beta$ -amyloid-PET as a surrogate for neurodegeneration severity.

Hypoperfused brain regions were highly correlated with those found to be impaired during neuropsychological

and MMSE scores, (C) and (D) partial correlation  $(r^2)$  of regional perfusion deficits and CERAD Plus sum scores

testing. The strongest regional association with neuropsychological test results was detected in the left temporal lobe, encompassing multiple structures involved in memory processing and linguistic abilities, like the hippocampus in the mesial temporal lobe or the temporal pole [30]. A strong agreement of left temporal lobe hypoperfusion with clinical testing in AD has already been shown in various MRI and FDG-PET/CT studies [2, 31-33]. Clinical testing with MMSE also showed an association with perfusion deficits in the bilateral inferior and posteromedial parietal lobe [34-36]. In comparison to MMSE testing, we noted a stronger correlation between CERAD-Plus sum scores and frontal perfusion impairments. The difference can be explained by the CERAD-Plus battery's increased focus on executive skills and semantic evaluations (e.g., in the subtests of semantic verbal fluency and the Boston naming test) that activate the frontal lobe [22]. Results in TMT A were linked not only to temporal perfusion deficits, but also to parietal and occipital perfusion abnormalities, attributable to the parietal lobes' established function in visuospatial orientation and visuomotor control [37] alongside the occipital lobes' known role in visual processing [38, 39]. Not only regional, but also the global perfusion deficit demonstrated strong associations with neuropsychological testing using MMSE and CERAD-Plus test battery. This agrees with a previous study demonstrating the efficacy of early-phase β-amyloid-PET in distinguishing the degree



Fig. 3 Association between perfusion deficits in predefined regions of interest and neuropsychological testing with MMSE and CERAD-Plus test battery A) Cognitive performance in MMSE and CERAD-Plus test battery in patients grouped according to their PET-based stage

 Table 3 Perfusion deficit in AD-related regions of patient groups

 stratified according to clinical severity expressed as volume-weighted

 mean z-score and standard deviation

	MMSE	MMSE	MMSE	MMSE	р
	28-30	24–27	18–23	10-17	
regions I/II	$-0.19 \pm 1.55$	$-0.32 \pm 1.18$	$-0.70 \pm 1.14$	$-1.44 \pm 1.80$	0.092
regions III/IV	$-1.01 \pm 0.62$	$-1.20 \pm 0.93$	$-1.74 \pm 0.99$	$-2.29\pm2.09$	0.020
regions V/VI	$-1.55 \pm 0.53$	$-1.62 \pm 0.64$	-2.16±0.97	-2.21±1.21	0.125

of hypoperfusion between Alzheimer's disease patients and healthy controls, and showing a significant correlation between the hypoperfusion in AD-related regions and MMSE scores [11]. Our results also corroborate previous research consistently showing strong associations between MRI assessed whole brain volume and disease severity and progression in AD [40–44].

evaluated with regional perfusion deficits in early-phase  $\beta$ -amyloid-PET. **B**) Perfusion deficits in predefined regions of interest in patients with differing test results in MMSE testing

Overall, disease severity as assessed by neuropsychological testing showed a higher association with left hemispheric perfusion deficits confirming previous results describing a left-leaning pattern of neurodegeneration and  $\beta$ -amyloid pathology in AD [31, 45–48].

In our study, regional perfusion deficits showed a better correlation than the summarized perfusion deficits in predefined regions that were oriented to the regions that are affected by tau-fibrils in histopathologic Braak-staging. This may be due to regions known to have a high tau burden, but not consistently showing a strong hypoperfusion in earlier studies, such as the temporal region [49].

In our study, early-phase  $\beta$ -amyloid-PET-based staging effectively classified the majority of patients across distinct clinical severities of dementia. Despite the exclusion of atypical patients, 19.5% of patients were classified as stage<sup>atypical+</sup>, a result that was unexpected. A similar percentage of Alzheimer's patients have an aberrant distribution of



**Fig. 4** Surface projections (3DSSP) of patients with different PETbased stages **A**) 3DSSP of a patient with subjective cognitive complaints (MMSE 28; CERAD Plus sum score 80), PET-based staging returned stage<sup>I-II+</sup>. **B**) 3DSSP of a patient with mild dementia (MMSE

23; CERAD Plus sum score 39), PET-based staging returned stage<sup>I-IV+</sup>.
C) 3DSSP of a patient with moderate dementia (MMSE 11; CERAD Plus sum score not assessable), PET-based staging returned stage<sup>I-VI+</sup>



Fig. 5 Multilinear regression of perfusion deficit and annual percentage decline of test results in neuropsychological testing (MMSE and CERAD) correcting for age, gender, and years of education

tau fibrils, yet there are known regions, such as the temporal lobe, where tau deposition and hypoperfusion do not correspond [49].

In our study, the percentage decline of clinical test scores was associated with temporal and parietal perfusion impairment. The minor improvement in test scores observed in a limited number of patients is likely attributable to daily fluctuations in cognitive performance. In line with our data, previous MRI perfusion and FDG-PET studies have extensively validated the association of regional perfusion impairment and cognitive decline with the best regional associations being reported in the hippocampus, the entorhinal cortex, and the posterior cingulate cortex [3, 50-52]. Also, frontal and parietal perfusion deficits have been described to significantly correlate with cognitive decline as disease progresses [53-56]. In conclusion,  $\beta$ -amyloid-PET may not only be useful for diagnostic purposes but also provides a tool to estimate patient-specific risk for cognitive decline and clinical progression in AD.

Until recently, therapeutic options available to patients with AD were confined to symptomatic treatments. However, antibodies targeting  $\beta$ -amyloid plaques have meanwhile received FDA approval and further promising targeted therapies aiming to mitigate cognitive decline are currently being developed. The various pathomechanisms of these drugs will eventually allow individualized therapeutic approaches. In order to evaluate therapeutic agents, biomarkers that correlate with disease severity and progression are needed. In our study, regional and global perfusion deficits measured by early-phase  $\beta$ -amyloid-PET were associated with current neuropsychological test results and clinical progression underscoring their potential for usage in clinical trials for assessing and staging neurodegeneration severity in AD. Various studies demonstrated a strong agreement between regional perfusion deficits in early-phase β-amyloid-, tau-, and dopamine-PET, regional perfusion deficits in perfusion MRI and hypometabolism assessed by FDG-PET [6, 10, 57–60]. Recently, the European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders were published [61]. According to the proposed diagnostic workflow, FDG-PET should be used in the workup of patients with a causal hypothesis of suspected AD, frontotemporal lobar degeneration or suspected motor tauopathy to assess the pattern of neuronal

injury [61]. Depending on the suspected clinical diagnosis and already measured biomakers, an additional assessment of CSF biomarkers is required [61]. The detected associations of this study underline the possibility to detect neuronal injury by early-phase  $\beta$ -amyloid-PET in parallel to assessing amyloid burden. A dual-phase acquisition protocol of β-amyloid-PET may therefore eliminate the need to perform further examinations. Also, in clinically unclear cases, the concurrent measurement of two biomarker categories in a one-stop-shop examination may be time-saving and cost-effective. However, especially in younger patients, atypical clinical presentations, or rapid progression of dementia, CSF examination remains essential to rule out potential differential diagnoses. Furthermore, early-phase β-amyloid-PET could represent an alternative to FDG-PET imaging regarding the prediction of cognitive decline. However, head-to-head studies will be needed to compare the predictive accuracy of early-phase β-amyloid-PET and FDG- and tau-PET, respectively.

Several limitations apply to our study. We acknowledge the comparatively low number of patients with follow-up data. Larger prospective studies will be needed to verify the detected association of early-phase *β*-amyloid-PET with future cognitive decline. Furthermore, PET-based staging followed the assumption that perfusion deficits are highest in regions with highest tau load. Despite many regions overlapping between tau deposition and neurodegeneration, the temporal decoupling and some different vulnerabilities make the patterns not completely fitting. Previous studies even suggested that hypoperfusion can precede tau deposition [62]. Our study lacks a correlation with histopathological data or tau-PET to confirm pathological tau fibrils in brain regions with reduced perfusion. Reduced regional perfusion is non-specific and may be related to other underlying pathologies such as LATE-pathology, synuclein, ischemic lesions or white matter changes. Therefore, further studies will be needed to evaluate the association of early-phase β-amyloid-PET-based staging with histopathologically confirmed Braak-stages. Also, there are currently no established cut-offs for the definition of pathological hypoperfusion in early-phase  $\beta$ -amyloid-PET. In our study, we used a modified AAL-atlas with a parcellation into 47 regions. While the temporomesial lobe encompassing several important structures of the memory system was not divided further into subregions, this approach is close to daily patient evaluation and may therefore be suitable for clinical routine. Moreover, in contrast to the diagnostic evaluation of the cerebral hypometabolism in FDG-PET, commercial softwares don't provide a built-in normal cohort for z-score evaluation of early-phase amyloid-PET yet. However, the assessment of perfusion deficits by early-phase  $\beta$ -amyloid-PET is very robust and easy to include in the acquisition process and

postprocessing workflow. Normal-cohort data could readily be implemented in the future, if early-phase  $\beta$ -amyloid-PET will further be established as a marker of neuronal injury.

Keeping these limitations in mind, our data reveal that global and regional perfusion deficits on early-phase  $\beta$ -amyloid-PET can serve as an objective index of clinical testing and may act as a prognostic marker of future cognitive decline in AD. The possibility to assess two biomarker categories in a one-stop-shop examination may reduce the need for additional diagnostic procedures assessing  $\beta$ -amyloid and neurodegeneration in the diagnostic work-up of patients with suspected AD.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00259-0 25-07175-5.

Author contributions Conceptualization, S.S., M.B. and F.V.; methodology, F. V. and S.S.; formal analysis, F. V., S.S.; acquisition of data: S.E., F.H., A. K., M.G., D.J., A.B., J.V., A.S., F.S., E.W., K.B., O.W.; data curation, F.V.; writing—original draft preparation, F.V., S.S.; writing—review and editing, M.B., M.S., F.E., N.F., C.P., A.B., J.V., B.R., R.P., E.W., G.H.; visualization, F.V., A.S.; supervision, M.B., S.S., J.L.

Funding Open Access funding enabled and organized by Projekt DEAL. JL reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche, consulting fees from Axon Neuroscience, EISAI and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent "Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies" (PCT/EP2024/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent "Pharmaceutical Composition and Methods of Use" (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. MB received speaker honoraria from GE healthcare, Roche, and LMI, and is an advisor of LMI and MIAC. NF reports speaker fees from Life Molecular Imaging, GE Healthcare, Eisai and consulting honoraria from MSD. KB received advisor and speaker honoraria as well as support for travel expenses by Eisai, Lilly Deutschland, Novo Nordisk, Biogen, Roche. JV served as a consultant for and received speaker fees from Eisai and Lilly. He received coverage for conference and travel expenses from Biogen, Eisai, Lilly, the Alzheimer's Association, the Austrian Alzheimer's Society and the German Society of Nuclear Medicine. FS received honoraria for advisory boards for Alexion, Amylyx and Alnylam. CP reports author fees from Thieme medical publishers, is inventor in a patent "Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies" (PCT/EP2024/053388) filed by LMU Munich and was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy- ID 390857198), the Thiemann Stiftung, Lüneburg Heritage, Friedrich-Baur-Stiftung and Else Kröner Fresenius Stiftung. SS was supported by the Friedrich-Baur-Stiftung and the FöFoLe program (LMU, Munich).

**Data availability** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

#### Declarations

**Ethics approval and consent to participate** The study was performed according to the Declaration of Helsinki (1991) and was approved by the local ethics committee (Medical Faculty, LMU Munich, Munich, Germany, application number 17–569). Written informed consent was obtained from every participant.

**Conflict of interest** The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

### References

- Jack CR Jr., et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62.
- Sorensen A, et al. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. Neuroimage Clin. 2019;21:101637.
- Torosyan N, et al. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur J Nucl Med Mol Imaging. 2017;44(8):1355–63.
- Beyer L, et al. Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. Neuroimage Clin. 2021;29:102535.
- Ewers M, et al. Cognitive reserve associated with FDG-PET in preclinical alzheimer disease. Neurology. 2013;80(13):1194–201.
- Schmitt J, et al. Dual-Phase beta-Amyloid PET captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284.
- Daerr S, et al. Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin. 2017;14:77–86.
- Vanhoutte M, et al. Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer's clinical syndrome. NeuroImage: Clin. 2021;31:102750.
- Tiepolt S, et al. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1700–9.
- Völter F, et al. Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamolamyloid-PET recordings. Eur J Nucl Med Mol Imaging. 2023;50(5):1384–94.
- Boccalini C, et al. Early-phase (18)F-Florbetapir and (18)F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2022;64(2):266–73.
- Myoraku A, et al. Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. Eur J Hybrid Imaging. 2022;6(1):2.

- Aye WWT, et al. Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease. Alzheimers Dement (Amst). 2024;16(2):e12601.
- Lesman-Segev OH, et al. Diagnostic accuracy of amyloid versus (18) F-Fluorodeoxyglucose positron emission tomography in Autopsy-Confirmed dementia. Ann Neurol. 2021;89(2):389–401.
- Ikonomovic MD, et al. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016;4(1):130.
- Lowe VJ, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561–71.
- Kotari V, et al. Early Tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. Alzheimers Res Ther. 2023;15(1):41.
- Malarte M-L, Nordberg A, Lemoine L. Characterization of MK6240, a Tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases. Eur J Nucl Med Mol Imaging. 2021;48(4):1093–102.
- Fleisher AS, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829–39.
- Folstein MF, Folstein SE, McHugh PR. Mini-mental State. A practical method for grading the cognitive State.of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
- Nilsson FM. Mini mental state examination (MMSE)– probably one of the most cited papers in health science. Acta Psychiatrica Scandinavica. 2007;116(2):156–7.
- Chandler MJL, Hynan LH, Barnard LS, Allen HD, Deschner G, Weiner M, Cullum MF. C.M., A total score for the CERAD neuropsychological battery. Neurology. 2005;65:5.
- Meyer PT, et al. Dual-Biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and <sup>11 C-Labeled Pittsburgh compound B. J Nucl Med. 2011;52(3):393–400.
- Senda M, et al. The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol ((1)(8)F) injection in healthy Japanese adult volunteers. Ann Nucl Med. 2015;29(7):627–35.
- Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI Single-Subject brain. NeuroImage. 2002;15(1):273–89.
- Available from: https://adni.bitbucket.io/reference/docs/UCBER KELEYAV1451/UCBERKELEY\_AV1451\_Methods\_Aug2018. pdf
- Biel D, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther. 2021;13(1):137.
- Kim R, et al. Validation of the conversion between the Mini-Mental state examination and Montreal cognitive assessment in Korean patients with Parkinson's disease. J Mov Disord. 2018;11(1):30–4.
- Lawton M, et al. Validation of conversion between mini-mental state examination and Montreal cognitive assessment. Mov Disord. 2016;31(4):593–6.
- Bubb EJ, Kinnavane L, Aggleton JP. Hippocampal diencephalic

   cingulate networks for memory and emotion: an anatomical guide. Brain Neurosci Adv. 2017;1(1).
- Rodriguez G, et al. Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Res. 2000;100(2):65–74.
- Tai H, et al. The neuropsychological correlates of brain perfusion and Gray matter volume in Alzheimer's disease. J Alzheimers Dis. 2020;78(4):1639–52.
- Berron D, et al. Early stages of Tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144(9):2771–83.

- Birn RM, et al. Neural systems supporting lexical search guided by letter and semantic category cues: a self-paced overt response fMRI study of verbal fluency. NeuroImage. 2010;49(1):1099–107.
- Baldo JV, et al. Verbal and design fluency in patients with frontal lobe lesions. J Int Neuropsychol Soc. 2001;7(5):586–96.
- 36. Ren X, et al. Decreased prefrontal brain activation during verbal fluency task in patients with somatoform pain disorder: an exploratory multi-channel near-infrared spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry. 2017;78:153–60.
- Dehaene S, Cohen L. Towards an anatomical and functional model of number processing. Math Cognition. 1995;1(1):83–120.
- Indovina I, Macaluso E. Occipital-parietal interactions during shifts of exogenous visuospatial attention: trial-dependent changes of effective connectivity. Magn Reson Imaging. 2004;22(10):1477–86.
- Abhang PA, Gawali BW, Mehrotra SC, Chap. 1 Introduction to Emotion, Electroencephalography, and Speech Processing, in Introduction to EEG- and Speech-Based Emotion Recognition, Abhang PA, Gawali BW, Mehrotra SC. Editors. 2016, Academic Press. pp. 1–17.
- Sluimer JD, et al. Whole-Brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology. 2008;248(2):590–8.
- Schott JM, et al. Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia. 2008;46(6):1732–7.
- 42. Henneman WJP, et al. Hippocampal atrophy rates in alzheimer disease. Neurology. 2009;72(11):999–1007.
- 43. Cover KS, et al. Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Res. 2011;193(3):182–90.
- Mak E, et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with lewy bodies. NeuroImage: Clin. 2015;7:456–62.
- Janke AL, et al. 4D deformation modeling of cortical disease progression in Alzheimer's dementia. Magn Reson Med. 2001;46(4):661–6.
- Thompson PM, et al. Dynamics of Gray matter loss in Alzheimer's disease. J Neurosci. 2003;23(3):994–1005.
- Thompson PM, et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex. 2001;11(1):1–16.
- Lubben N, et al. The enigma and implications of brain hemispheric asymmetry in neurodegenerative diseases. Brain Commun. 2021;3(3):fcab211.
- 49. St-Onge F, et al. Tau accumulation and its Spatial progression across the Alzheimer's disease spectrum. Brain Commun. 2024;6(1):fcae031.

- de Leon MJ, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98(19):10966–71.
- Chao LL, et al. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord. 2010;24(1):19–27.
- Huang C-W, et al. Cerebral perfusion insufficiency and relationships with cognitive deficits in Alzheimer's disease: A multiparametric neuroimaging study. Sci Rep. 2018;8(1):1541.
- 53. Dong H, et al. Association between Gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease. Front Aging Neurosci. 2023;15:1129051.
- 54. Austin BP, et al. Effects of hypoperfusion in Alzheimer's disease. J Alzheimers Dis. 2011;26(Suppl 3):123–33.
- 55. Binnewijzend MA, et al. Cerebral perfusion in the predementia stages of Alzheimer's disease. Eur Radiol. 2016;26(2):506–14.
- 56. Burton EJ, et al. Medial Temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009;132(Pt 1):195–203.
- Yoon HJ, et al. Dual-phase (18)F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer's disease. Neuroimage Clin. 2021;31:102773.
- Peng S, et al. Dynamic<sup>18F-FPCIT PET: quantification of Parkinson disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session. J Nucl Med. 2021;62(12):1775–82.
- Guehl NJ, et al. Measurement of cerebral perfusion indices from the early phase of [<sup>18F]MK6240 dynamic Tau PET imaging. J Nucl Med. 2023;64(6):968–75.
- Dallaire-Théroux C, et al. Braak neurofibrillary tangle staging prediction from in vivo MRI metrics. Alzheimers Dement (Amst). 2019;11:599–609.
- 61. Frisoni GB, et al. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol. 2024;23(3):302–12.
- Kapadia A, Billimoria K, Desai P, Grist JT, Heyn C, Maralani P, Symons S, Zaccagna F. Hypoperfusion precedes tau deposition in the entorhinal cortex: a retrospective evaluation of ADNI-2 data. J Clin Neurol. 2023;19(2):131–7. https://doi.org/10.398 8/jcn.2022.0088. Epub 2023 Jan 2. PMID: 36647226; PMCID: PMC9982189.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.